Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models

Cancer Biology and Therapy

Volumn 9, Issue 3, 2010, Pages 176-182

  Lu, Chunhua ^a   Shahzad, Mian M K ^a,b   Moreno Smith, Myrthala ^a   Lin, Yvonne G ^a   Jennings, Nicholas B ^a   Allen, Julie K ^a   Landen, Charles N ^a   Mangala, Lingegowda S ^a   Armaiz Pena, Guillermo N ^a   Schmandt, Rosemarie ^a   Nick, Alpa M ^a   Stone, Rebecca L ^a   Jaffe, Robert B ^c   Coleman, Robert L ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aptamer; AX102; Bevacizumab; Endothelial cell; Ovarian cancer; PDGF B; Pericyte

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; AX 102; BEVACIZUMAB; CYCLINE; DOCETAXEL; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR B; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER COMBINATION CHEMOTHERAPY; CELL MATURATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; OVARY CARCINOMA; PERICYTE; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APTAMERS, NUCLEOTIDE; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; LONGITUDINAL STUDIES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PACLITAXEL; PERICYTES; PROTO-ONCOGENE PROTEINS C-SIS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953604802     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.3.10635     Document Type: Article

References (32)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3:65-71.
2. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98:4605-10.
3. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-34. (Pubitemid 36910021)
4. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-5.
5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. (Pubitemid 44917502)
6. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
7. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153:1249-56. (Pubitemid 28465848)
8. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002; 161:1917-24. (Pubitemid 35265548)
9. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 2007; 25:5165-71.
10. Sims DE. The pericyte - a review. Tissue Cell 1986; 18:153-74.
11. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res 1996; 32:687-98.
12. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15:102-11. (Pubitemid 40127638)
13. nd ed), Humana Press, Inc., Totowa (NJ) 117-32.
14. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007; 13:4209-17.
15. Lu C, Landen C, Kim T, Kamat A, Han L, Li Y, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for human ovarian cancer. Proc Am Assoc Cancer Res 2006; 47.
16. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 2008; 198:477.
17. Aptamers WJ. Encyclopedia of analytical chemistry 2000; 4848-71.
18. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62:5476-84.
19. Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007; 67:7358-67. (Pubitemid 47206566)
20. Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 1999; 154:169-79. (Pubitemid 29031624)
21. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
22. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3:24-40.
23. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008; 5:194-204.
24. Kelly JD, Haldeman BA, Grant FJ, Murray MJ, Seifert RA, Bowen-Pope DF, et al. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. J Biol Chem 1991; 266:8987-92.
25. Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays 2001; 23:494-507.
26. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004; 23:2800-10.
27. Tejada ML, Yu L, Dong J, Jung K, Meng G, Peale FV, et al. Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res 2006; 12:2676-88.
28. Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 2004; 93:78-86.
29. Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003; 162:1083-93.
30. McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007; 117:2114-22.
31. Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res 2005; 11:306-14.
32. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 2004; 10:897-908.